Cardiol Therapeutics (NASDAQ:CRDL) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Cardiol Therapeutics (NASDAQ:CRDLFree Report) in a research note published on Friday, Benzinga reports. The brokerage currently has a $9.00 price objective on the stock.

A number of other analysts also recently weighed in on CRDL. Canaccord Genuity Group increased their price target on shares of Cardiol Therapeutics from $6.00 to $8.00 and gave the company a buy rating in a report on Thursday, May 23rd. Canaccord Genuity Group increased their price target on shares of Cardiol Therapeutics from $6.00 to $8.00 and gave the company a buy rating in a report on Thursday, May 23rd. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of Buy and an average target price of $7.00.

Check Out Our Latest Research Report on CRDL

Cardiol Therapeutics Price Performance

NASDAQ CRDL opened at $2.41 on Friday. The company has a current ratio of 2.81, a quick ratio of 2.81 and a debt-to-equity ratio of 0.01. Cardiol Therapeutics has a 1 year low of $0.66 and a 1 year high of $2.81. The company has a fifty day simple moving average of $2.09 and a 200 day simple moving average of $1.51. The company has a market cap of $164.77 million, a P/E ratio of -6.89 and a beta of 0.99.

Cardiol Therapeutics (NASDAQ:CRDLGet Free Report) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.04). On average, sell-side analysts predict that Cardiol Therapeutics will post -0.25 EPS for the current year.

Hedge Funds Weigh In On Cardiol Therapeutics

A hedge fund recently raised its stake in Cardiol Therapeutics stock. Tejara Capital Ltd increased its position in shares of Cardiol Therapeutics Inc. (NASDAQ:CRDLFree Report) by 29.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 645,457 shares of the company’s stock after purchasing an additional 148,396 shares during the quarter. Tejara Capital Ltd owned approximately 1.00% of Cardiol Therapeutics worth $578,000 at the end of the most recent quarter. 12.49% of the stock is currently owned by institutional investors and hedge funds.

About Cardiol Therapeutics

(Get Free Report)

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.

Recommended Stories

Analyst Recommendations for Cardiol Therapeutics (NASDAQ:CRDL)

Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.